A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder

Area of Science:

• Neuroimmunology
• Central Nervous System Disorders
• Autoimmune Diseases

Background:

• Neuromyelitis optica spectrum disorder (NMOSD) is a rare, disabling autoimmune disease affecting the central nervous system.
• Relapses in NMOSD can lead to severe disability, including blindness, paralysis, and death, distinguishing it from multiple sclerosis.
• Recent advancements include the development and integration of targeted immunotherapies into the clinical treatment of NMOSD.

Purpose of the Study:

• To pragmatically evaluate the current therapeutic landscape for Neuromyelitis optica spectrum disorder (NMOSD).
• To assess recent clinical trials and post-marketing data for emerging NMOSD therapies.
• To review contemporary considerations in NMOSD management, including during pregnancy and SARS-CoV-2 infection.

Main Methods:

• Review of recent clinical trials and post-marketing data for NMOSD treatments.
• Comparative analysis of newer targeted immunotherapies (rituximab, inebilizumab, satralizumab, eculizumab, ravalizumab) against older agents.
• Inclusion of contemporary issues impacting NMOSD treatment strategies.

Main Results:

• Significant improvements in NMOSD morbidity and mortality observed due to earlier recognition and diagnostic accuracy.
• Advent of effective, targeted therapies has dramatically shifted treatment outcomes.
• Disease-free survival is now an achievable goal for NMOSD patients with current and emerging treatments.

Conclusions:

• The therapeutic landscape for NMOSD has been transformed by targeted immunotherapies.
• Selection of maintenance therapy requires careful consideration of individual patient factors and treatment accessibility.
• Ongoing research with numerous agents in trials suggests a promising future for NMOSD management, with disease-free survival as a realistic objective.